|By Marketwired .||
|February 19, 2014 08:32 AM EST||
NEW YORK, NY -- (Marketwired) -- 02/19/14 -- NeoStem, Inc. (NASDAQ: NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that Dr. Robin L. Smith, Chairman and CEO, was interviewed live on Clear Channel's "The Traders Network" hosted by Michael Yorba. This was Dr. Smith's second appearance on The Traders Network. In a two-part interview, Dr. Smith explained the Company's 2014 goals, 2013 achievements, and the increased visibility the Company is achieving in the cell therapy industry.
When asked why investors are interested in NeoStem, Dr. Smith explained how NeoStem has addressed three key risks that investors often assess before investing in a stem cell company; financing, patient enrollment and manufacturing capabilities. NeoStem has addressed these risks by, first, raising over $40 million this past October in its latest round of fundraising. Second, completing enrollment in its Phase 2 clinical trial testing AMR-001, its lead product candidate for cardiovascular disease, demonstrating management's skill in advancing product candidates through the clinical trial regime. And lastly, as the Company has internal manufacturing capabilities through its wholly owned subsidiary, Progenitor Cell Therapy (PCT), there are lower risks and uncertainties associated with manufacturing its cell therapy candidates.
Mr. Yorba and Dr. Smith discussed NeoStem's pipeline of proprietary cell therapy products, which continues to develop, most notably, NeoStem's completion of enrollment in its PreSERVE AMI Phase 2 clinical trial in December 2013, investigating the Company's most advanced product candidate, AMR-001, in preserving heart function after a severe heart attack. Data read out is expected in Q3 2014, and the Company is also exploring AMR-001 for chronic heart failure and traumatic brain injury. NeoStem also continues to advance its T regulatory cell program with the goal of developing treatments for immune modulated diseases such as type 1 diabetes, and inflammatory conditions such as steroid resistant asthma. Finally, NeoStem continues to develop its very small embryonic-like stem cell (VSEL Technology) platform in preclinical models with the goal of advancing into early clinical studies to explore the therapeutic potential of VSEL Technology in indications such as bone repair, healing complex skin and soft tissue wounds, and age-related macular degeneration.
In 2013, for the second year in a row, NeoStem was named the number one fastest growing company and number eleven nationally on Deloitte's Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Deloitte looks at revenue and growth over a five year growth period as a benchmark. When Mr. Yorba asked Dr. Smith about winning this award, she noted that the Company was really proud to have won this award and to be in the company of such highly esteemed peer companies that were also in the running for the award.
Mr. Yorba and Dr. Smith also discussed NeoStem's unique model of growth. Instead of simply building the Company organically, NeoStem has grown through a series of acquisitions, and as such has become one of the fastest growing companies in its sector. NeoStem has completed five M&A transactions, one divestiture, and raised over 180 million dollars, enabling it to bring in key assets. As Dr. Smith explained, growing the Company in this manner has allowed NeoStem to acquire great talent, and the assets to potentially lead the industry. Speaking of NeoStem's revenue-generating operations through PCT, Dr. Smith said, "I think having the manufacturing is a real edge for us because we can generate revenues from the industry, we can lower the cost of goods, we can focus on things that the industry needs as a whole, and not only does it benefit our clients, but it benefits our internal development. We've created a very unique model that seems to be exciting to Wall Street and investors."
To hear the entire Clear Channel interview, click on the archive stream links below.
Interview Archive Segment 1 (9min, 37sec):
Interview Archive Segment 2 (10min, 41sec):
Network: Clear Channel
Show: The Traders Network
Station: DFW 1190 AM KFXR
Host: Michael Yorba
Mr. Yorba remarked, "We give NeoStem two thumbs up and expect to see big things from Dr. Robin Smith in the near future. Exciting times and an exciting company."
About Clear Channel: Clear Channel Media and Entertainment's more than 840 radio stations offer programming nationwide. Individual station brands connect with diverse audiences in local markets across the country reaching more than 112 million listeners. www.clearchannel.com.
About Michael Yorba: Michael Yorba -- featured host of Clear Channel's DFW 1190 AM in Dallas-Ft. Worth. For the past six years he has been integrally involved with the media industry in various capacities including building an IPTV Network, developing, producing and hosting a daily one hour talk show called Commodity Classics and then later The Traders Network, defined as an audience empowered interactive financial program that has been broadcast live on internet television and radio. His focus has been on derivative portfolio analysis for individual and corporate clients through the use of futures and futures options, managed funds, and Forex. www.yorbamedia.com
About NeoStem: NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com
Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts as well as efforts towards commercialization of cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2522941
NeoStem Investor Contact
LifeSci Advisors, LLC
+1 (646) 597-6979
NeoStem Media Contact
Manager of Communications and Marketing
+1 (212) 584-4173
MUNCmedia Public Relations
+1 (917) 409-8211
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Feb. 20, 2017 09:15 PM EST Reads: 868
"Plutora provides release and testing environment capabilities to the enterprise," explained Dalibor Siroky, Director and Co-founder of Plutora, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
Feb. 20, 2017 09:15 PM EST Reads: 4,471
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
Feb. 20, 2017 08:45 PM EST Reads: 4,307
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.
Feb. 20, 2017 08:30 PM EST Reads: 1,482
The security needs of IoT environments require a strong, proven approach to maintain security, trust and privacy in their ecosystem. Assurance and protection of device identity, secure data encryption and authentication are the key security challenges organizations are trying to address when integrating IoT devices. This holds true for IoT applications in a wide range of industries, for example, healthcare, consumer devices, and manufacturing. In his session at @ThingsExpo, Lancen LaChance, vic...
Feb. 20, 2017 07:00 PM EST Reads: 8,212
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @CloudExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
Feb. 20, 2017 06:15 PM EST Reads: 985
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
Feb. 20, 2017 06:15 PM EST Reads: 798
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
Feb. 20, 2017 05:45 PM EST Reads: 481
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
Feb. 20, 2017 05:30 PM EST Reads: 2,239
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smart...
Feb. 20, 2017 05:30 PM EST Reads: 3,897
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, discussed the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports.
Feb. 20, 2017 05:15 PM EST Reads: 960
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Feb. 20, 2017 02:45 PM EST Reads: 472
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
Feb. 20, 2017 02:15 PM EST Reads: 1,100
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
Feb. 20, 2017 01:15 PM EST Reads: 454
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of D...
Feb. 20, 2017 01:00 PM EST Reads: 5,863